Australia’s NHMRC backs conditional puberty blockers for trans children in new guidelines
Australia’s National Health and Medical Research Council (NHMRC) on Monday released interim national clinical practice guidelines advising that puberty blockers can be appropriate for gender-affirming care of children in certain circumstances, after a year-long review of international evidence. The federal government commissioned the commonwealth-funded council last year after Queensland and Northern Territory governments banned the treatments in public hospitals; New Zealand later imposed similar bans despite health-sector opposition and warnings of harm to children. The interim advice could press other states and territories to revisit their positions.
The council rejected “wait and see” and similar alternatives as withholding care that can affect a young person’s physical and mental health, wellbeing and ability to function. Puberty blockers stop the body producing oestrogen and testosterone; they have been used since the 1970s for conditions such as precocious puberty and in gender-affirming care since the 1990s. Hormone replacement therapy uses synthetic hormones for cancers, endometriosis and gender incongruence. Both are common, long-standing treatments covered by the Pharmaceutical Benefits Scheme for cisgender patients.
The guidelines do not require a child to be distressed before treatment for gender incongruence and say a multidisciplinary team should be decided case by case. Doctors should prioritise the young person’s best interest and wellbeing and respect their autonomy. Gender incongruence is defined as a difference between a person’s gender and sex recorded at birth and is not a mental health disorder; some young people also have significant distress, known as gender dysphoria. The advice largely aligns with AusPATH’s existing Australian standards, is based on a multidisciplinary committee and a systematic evidence review, and notes unjust health disparities for trans and gender-diverse young people from stigma, discrimination and barriers to care. Public consultation on “Advice on the use of puberty suppressants in the care of trans and gender-diverse people aged under 18” is open until 18 January. Full guidelines covering other care, including gender-affirming hormones, are expected in 2028. The NHMRC is an independent statutory agency and among the world’s largest medical research organisations.
Continue in the app — vote & join in ➔